New research publication: First-in-class trispecific VHH-Fc based antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 and variants|
New research partnership with China Resources Biopharmaceutical
510-397-6439
3541 Investment Blvd. Suite 3, Hayward, CA 94545 USA